Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.

The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.

Why It Was Studied

Diabetes insipidus was not identified in any patients after the operation.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

The patients were treated with pasireotide LAR with or without octreotide LAR for two years and underwent transsphenoidal adenomectomy.

How the Study Was Run

The design is described as randomized and double-blind.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.

The methods mention a period of two years.

What Was Measured

The subject headings attached to it are Acromegaly, Human Growth Hormone, Insulin-Like Growth Factor I, Magnetic Resonance Imaging, Octreotide, Pituitary Neoplasms and Somatostatin.

The authors tagged it with the keywords pasireotide, preoperative treatment, somatostatin analogue and transsphenoidal adenomectomy.

What This Means in Plain Language

The paper is a randomized and double-blind study of Octreotide and Somatostatin over two years.

The publication is from 2016 (Journal of the Formosan Medical Association = Taiwan yi zhi), a journal based in Singapore.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.